Health and Social Care Board

Interface Pharmacist Network Specialist Medicines

Erenumab (Aimovig®) for migraine

GP Information Sheet

Introduction

Erenumab is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor, thus preventing its biological activity. Elevated blood concentrations of CGRP have been associated with migraine attacks.

Erenumab can be considered an appropriate option for patients suffering from more than 4 migraine days per month that are over the age of 18 and would benefit from treatment.

In Northern Ireland, erenumab (Aimovig®) is accepted for use as an option for preventing migraine in adults, only if:

- they have 4 or more migraine days a month.
- at least 3 preventive drug treatments have failed.
- the 140 mg dose of erenumab is used and the company provides it according to the commercial arrangement.

For further information see NICE TA682 https://www.nice.org.uk/guidance/ta682

Usual Dosage and Administration

The recommended dose is 140mg given subcutaneously once monthly.

Erenumab is initiated by secondary care who will also arrange training to support self-administration by the patient and prescribed and dispensed in primary care.

After training, patients may self-inject erenumab.

Sharp boxes of 4 Litre should also be prescribed.

Available as

Aimovig® 140 mg solution for injection in pre-filled syringe (140 mg erenumab).

Store in a refrigerator (2°C - 8°C). Do not freeze.

Keep the pre-filled syringe in the outer carton in order to protect from light.

After removal from the refrigerator, Aimovig must be used within 14 days when stored at room temperature (up to 25°C), or discarded. If it is stored at a higher temperature or for a longer period it must be discarded.

Monitoring Requirements

There is no monitoring required for this agent itself.

Response to treatment is assessed by the specialist at clinic appointment.

Adverse Effects, Precautions and Contraindications

Commonly reported side effects are administration site conditions: injection site pain, injection site reactions, injection site erythema, injection site pruritus, injection site bruising, injection site swelling, pruritus, rash, urticaria, constipation, vertigo, anaphylaxis and angioedema.

Common Drug Interactions

No drug interaction studies have been conducted. No pharmacokinetic drug interactions are expected based on the characteristics of erenumab.

Communication

For any queries relating to this patient's treatment with erenumab, please contact the specialist.

This information is not inclusive of all prescribing information and potential adverse effects.
Please refer to full prescribing data in the SPC at www.medicines.org.uk or the BNF

Date Prepared: January 2022 Date of review: January 2027